- Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutationsWang, Jie; Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, XiaoliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarkerZhou, Qing; Wu, Lin; Jiang, Bo; Du, Yingying; Wang, Buhai; Hu, Xiaohua; He, Yong; Zhao, Mingfang; Yao, Yu; Cui, Jiuwei; Dong, Xiaorong; Zhang, Haibo; Ma, Rui; Wang, Huijuan; Zhang, Jian; Xia, Jinjing; Zhang, Yanni; Hayslip, John W.; Zhu, Andrew X.; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Perioperative toripalimab plus platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study.Lu, Shun; Wu, Lin; Zhang, Wei; Zhang, Peng; Wang, Wenxiang; Fang, Wentao; Xing, Wenqun; Chen, Qixun; Mei, Jiandong; Yang, Lin; Tan, Lijie; Sun, Xiaohong; Xu, Shidong; Hu, Xiaohua; Yu, Guohua; Yu, Dongliang; Shan, Jinlu; Yang, Nong; Chen, Yuping; Tian, HuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2023-11 To 2023-11.被引 29
会议论文
Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.
12阅读
